canadian online pharmacy rx female viagra for sale canadian online pharmacy rx canadian online pharmacy best generic cialis super active canadian online pharmacy rx





Rambler's Top100




Multidisciplinary PRIMAVERA MEDICA Medical Center was founded in 1993. Its identifying feature is attaining highest therapeutic efficiency based on application of METABOLIC THERAPY. Traditionally PRIMAVERA MEDICA investigates and treats diseases considered as having no prospects regarding outcome, bearers of such diseases are regarded as hopeless, while contemporary medicine either does not possess an adequate treatment potential or the efficiency of treatment leaves much to be desired from the point of view both of the doctor and the patient. In other words, when PRIMAVERA MEDICA Medical Center lets the public know of the treatment of a particular disease it means that METABOLIC THERAPY is a method of choice for that particular pathology (i.e. the company proposes the most efficient method available).

The human body is a balanced system that involves millions of metabolic processes. Its known that the chains of metabolic processes are interrelated on the basis of the mechanism of self-regulation. Its obvious that a failure of any reaction results in particular disorders and could serve a cause of a disease. Its equally obvious that to treat such a disease its necessary to impact the defective metabolic link. Such an effect could be achieved primarily through application of metabolic agents of natural origin. Naturally, because of the above mentioned reasons, these products are safe, which means they do not cause complications and are not associated with side reactions. Since METABOLIC THERAPY provides for accurate pathogenetic intervention aimed at a defective link of the functional and biochemical system the biochemical result does not take long to appear.

In the course of 16 years more than 200000 patients have turned to our Center and were treated of various diseases




this section is meant for specialists

and particularly meticulous readers

Our patients often ask us: What is metabolic therapy about? What is the effect of the drugs? What is the point of the therapy? Ill try to answer these questions underneath. Regretfully I can not resort to the language of popular literature for fear of whittling away the very core of the subject.
Scientific and medical center Primavera medica was founded in 1993. Back at that time our presumptions were based on the nerve cell repair phenomenon. At the beginning of the 1990s it was a revolutionary approach.
In subsequent years, through the endeavors undertaken by scientists from many countries it was convincingly shown that neurogenesis (generation of nerve cells) continues in the postnatal period and presumably takes place even in the advanced age gradually slowing down.
Its obvious that any kind of problems occurring in the course of pregnancy (medical conditions of the mother, fetoplacental insufficiency, virus diseases) that result in hypoxia and, consequently, trigger a free radicals formation process disturb development of a certain fetus brain structure. The above means that the pluripotent cells migrating during the period into this area from peri- and subventricular areas do not differentiate into neuronal or gliotic elements, but on the contrary die through apoptosis or aponecrosis as a result of the free radical conflagration. Eventually, such abnormalities as, for example, brain cortex, corpus callosum or cerebellum hypoplasia, may be diagnosed in the postnatal period.

Thus, the brain of such a baby experiences brain tissue deficiency, which often goes together with ventricular enlargement. It is clear that the insufficient neuronal and gliotic cells cannot ensure the normal function of this structure and are sure to be working in an over-intensive mode, i.e. in a permanent stressful situation. As a result, the Red-ox homeostasis is still disturbed in this area. Figuratively speaking, the free radical conflagration is ablaze against the background of abundant dicarboxylic excitatory neurotransmitters and deficient inhibitory ones. Thus, the neuronal stem cells migrating from the germinal area are doomed to perish.

The present world medical science identifies the following nosological entities resulting from perinatal pathology: infantile cerebral paralysis in one form or another (I mean spastic, hyperkinetic, atonic-astatic paralyses), oligophrenia, autism. It should be noted that we failed to find any intelligible molecular, biochemical or neurophysiological explanation of these states in available literature. There are just general references to disrupted formation of the pyramidal tract in case of spastic states, problems of the subcortical structures in case of the hyperkinetic form, etc. On the other hand, many physicians know that some antiepilepsy drugs reduce pyramidal spasticity and one can observe reduced epileptic equivalents during treatment of hyperkinetic disorders.
It is necessary to emphasize that one should not strive to treat spasticity using one means and the atonic-astatic form of cerebral paralysis using another one. The same refers to treatment of psychoverbal retardation both of hereditary and nonheritable origin. It is brain lesion that must be treated. How?
In our paper we proceed from the following theses:
1. A necessary basic condition is prescription of polyantioxidant therapy. The inventory of Primavera medica includes several groups of relevant drugs influencing:
a) superoxide dismutase with its histidine component as well as copper- and zinc-containing active site together with catalase;

b) growth of the pool of the glutathione complex the most powerful antioxidant intracellular substance with its major thiol component of this tripeptide;

c) growth of the pool of brain carnosine a unique dipeptide, especially considering its buffer properties;

d) break of the free radical chain during peroxidation of lipids of cell membranes due to use of high-carbon aliphatic compounds with a high number of olefinic bonds.

2. The second group of metabolic therapeutic agents from the inventory of Primavera medica is a complex of drugs aimed at recovery of the energy function of the cells.
One of them, Dehol, for example, includes oxalate and citrate the key substrates governing the rate of the tricarboxylic acids cycle.
It should be noted that Red-ox homeostasis normalization stops efflux of reductive equivalents from mitochondria into cytoplasm, which ensures reparation of the electronic-transport system of mitochondria with oxidation phosphorylation coupling.
3. An important component of the therapy is certain to be relief of the stress of neuronal cells by blocking NMDA and not NMDA transmission. This allows more sparing functioning of the excessively stressed neurons. To that end, we use Glucaprim-MG and Cerebron: aspartate- and glycin-containing preparations associated with Mg++, which allows noncompetitive inhibition of the relevant cell receptors.
In case of a more marked deficit or damage of the neuronal tissue accompanied by epilepsy manifestations use is also made of Cerebron-P, an AMPA-receptor blocker due to competitive inhibition.
4. It is impossible to achieve greater harmonization of work both of neuronal and gliotic brain components in the situation of cell deficit of overstressed functioning without using the drugs stimulating GABA- and glycin-ergic inhibition. To that end, we use drugs increasing the pool of -aminoacids: glycin, GABA, taurin. It is known that oral administration of taurin or GABA does not ensure the desired effect. Taurin does not penetrate the blood-brain barrier. Therefore, one has to use precursor substrates metabolizing into the necessary ligands. Such drugs include Aminovil-P, Oldarin, Glucaprim-P.
It should be noted that due to their formula some drugs are dual purpose. Such drugs include Oldarin and Aminovil-P (antioxidant and inhibitory neurotransmitter action).
One should also remember about GABA-ergic interneurons and associative neurons (Renshaw cell type by the mechanism of their action). Hence, inadequate therapeutic measures may include the tactics of one-way intensification of the inhibitory impact or accentuation on reduction of excitatory glutamate-transmission (this results in reduced inhibitory action of interneurons). Besides, this may lead to an adverse inhibitory effect resulting in disinhibition of neurophysiological processes. A proper (though not the only one) tactics seems to be the tactics of pharmacological increase of inhibitory innervation (with the help of a group of drugs). In both cases the use of the group of drugs is conditioned by different mechanisms of action (including the points of application of each of them).
5. The possibility of reciprocal influence on acetylcholine neurotransmission allows application of iminogel and iminol as well as aminostimunol. Iminogel and iminol depress the action of acetylcholine while aminostimunol potentiates it.
Therefore, inhibition of acetylcholine neurotransmission is used in case of dystonia of young children, hyperkinesias, pyramidal spasticity, osteochondrosis pain syndrome. On the contrary, aminostimunol potentiates the action of acetylcholine, which is successfully used to improve memory and other intellectual functions.
6. Joint application of vitorat and aminopurinol preparations allows to reduce hypoxanthine breakdown and simultaneously to intensify purine synthesis thus influencing purine-ergic transmission. This results in the certain physiological effects, such as sedative, anticonvulsive and hypotensive action.
7. To regulate neuronal processes it is not enough to impact excitatory-inhibitory mechanisms only. This system is strongly affected by other players as well: the so-called modulators, i.e. a numerous team including dopamine, acetylcholine, serotonin, monoamines, P substance, etc. (apart from modulating effect these regulators also have their own significance).
8. The last group of metabolic therapeutic drugs of Primavera medica is used to develop cognitive functions, to improve childrens capacity to study. The mechanism of their action is considerable acceleration of NMDA-ergic transmission combined with the possibility of impacting LTP (Long-Term Potentiation) or LTD (Long-Term Depression) processes. It is obvious that this group of drugs (these are Vitamikst-P, Neoprim-P, Glucaprim-P) should be used upon receiving a certain result from the previous stage of metabolic therapy.
9. The integrated approach of metabolic therapy of Primavera to the problem also considers the possibility of influencing neuroimmunological mechanisms. Dysimmunity may result from imbalance of various neurotransmitter systems. Depression of immunoprotection functions may arise in case of depressed dopamine-, acetylcholine- and GABA-ergic neurotransmission as well as in case of increased activity of serotonergic transmission in certain brain structures being part of the neuroimmunoregulatory system. Therefore, neurochemical correction of nervous regulation mechanism results in enhanced immunity.
It should be considered that activation of NDMA-neurotransmission (in case of its insufficiency) conditions both the level of work of the cortex and other important brain structures, for example, the pituitary-hypothalamic area. Normalization of the work of the hypothalamic-pituitary system (being the chief regulator of the endocrine system of the body) normalizes the function of endocrine glands.
Therefore, children with ICP or psycho-speech delay are often undersized and frail. In these cases metabolic therapy ensures both elimination of neurologic or intellectual deficit and accelerated physical development and growth.
We suppose that the same mechanism of regulating pituitary-hypothalamic deficiency by means of metabolic therapy may succeed in quite a different branch of medicine: gynecology for sterility treatment.
Thus, the general strategy of the therapy comes down to ensuring conditions for adequate neurogenesis with replenished brain tissue deficit. The long-term experience shows that severe brain lesion requires metabolic care of the child for 2.5 4 years. In less complicated situations we have satisfactory results within 2-5 months. It should be noted that the first marked signs of therapeutic effectiveness are already identified on the 2nd 3rd day from the start of the treatment.
And one more essential remark. Treatment should never considered completed even when very good clinical results have been achieved. The nervous system keeps forming and developing and there are critical periods conditioned by periodic catarrhal diseases, stress situations and, eventually, puberty. This means that the compensated, yet initially impaired nervous system will periodically need metabolic support. I would like to make a special point: one should start treatment as early as possible, better in the first postnatal days, especially in case of immature infants. In such cases the plastic babys brain and highly intensive neurogenesis appreciate metabolic assistance more highly.
Not everything given in this section was probably clear to some readers. However, the idea was, firstly, to substantiate convincingly the major provisions of the metabolic therapy concept of Primavera medica and, secondly, to show that our metabolic therapy has rather a complete inventory of the means allowing diversified impact on defective zones of various pathological processes, thus ensuring adequate functioning of the brain and the nervous system as a whole.



In the course of our work we have seen that the brain of every human, a healthy one, the more so a sick one, is unique in terms of its morphofunctional, neurotransmitter, immunochemical and electrophysiological characteristics.
To understand brain functioning our medicine currently has, in fact, only the electrophysiological method, i.e. EEG (apart from the clinical method). Electroencephalography is indeed a sensitive method, and EEG changes during the day depending on ones sleep or wake, fatigue, tension of some activity. EEG also changes after taking a certain medication. It is important to understand that the EEG of patients with the same diagnosis and clinical implications after taking similar medications will change differently.
Therefore, in especially complicated cases we make an EEG, then the patient takes the medication and we make another EEG 1-2 hours later. Comparative analysis of these 2 examinations (using histograms, spectral analysis and mapping) allows to understand specific features of the neurofunctional mechanisms of brain lesion and the possibility of impacting the defect by this medication. After several checks of this kind (EEG-monitoring) one can select an accurate treatment regimen and correctly achieve the intended therapeutic result.

You cannot fool the brain. Figuratively speaking, during EEG monitoring we can see whether the brain likes the proposed medication or not.

The aforesaid about selection of a treatment regimen using EEG monitoring with subsequent EEG control during treatment is especially relevant in treatment of epilepsy. Moreover, we consider it inadmissible to prescribe any medications (both metabolic and traditional antiepileptic agents) for this disease without EEG monitoring.
During the course of thoroughly selected treatment the clinical state of the patient improves (both motor and cognitive functions). The clinical improvement obviously reflects normalization of neurotransmitter and electrophysiological processes in the brain. Therefore, it is also clear that further treatment (more often during the next course) requires a modified therapeutic regiment, again using EEG monitoring.
Medical center Primavera medica has 2 EEG rooms. A third one is being arranged, however, given the growing need for this examination.


(perinatal encephalopathy, infantile cerebral paralysis, traumatic brain injury, psycho-speech delay, autism, genetic diseases, logoneurosis).

We have already written quite a lot about the effectiveness of metabolic therapy in all these severe pediatric diseases (one can see these materials on our official web-site
The treatment techniques have been worked out and the therapy tactics and strategy have been refined. Over the recent year the treatment results have gained more significance due to introduction of EEG monitoring and new metabolic preparations.
Physicians of Medical center Primavera medica have an extensive experience (over 100000 children have received treatment). Unmasked clinical studies have been conducted in various clinics, scientific papers have been published, scientific reports have been made at international symposia (Germany, the Czech Republic, the USA), guidelines for use of our drugs have been approved.

It should be emphasized that metabolic therapy should be used together with other treatment methods. Metabolic therapy normalizes neurochemical and electrophysiological processes in the brain tissue, provides the basis for formation and differentiation of new elements of the neural tissue. All this provides the basis for normal brain work. Therefore, during and after treatment it is necessary to add rehabilitation actions: special exercise therapy, training classes, speech correction. These should be special exercises aimed at training proper motor skills rather than massage, acupuncture or manual therapy.

And the last point. To avoid such diagnoses as ICP, oligophrenia, etc. that proceed from perinatal encephalopathy in the life of children the child should be treated during its first year already when neurogenesis is most intensive and the childs brain is more plastic.



These problems are also related to metabolic processes, primarily in the brain.

It has been convincingly proved that retention of new information and memory protein formation in hippocampus, for example, occur through activation of the so-called NMDA- and AMPA-receptors with subsequent activation of the caspase enzymatic system. The neurotransmitters activating these NMDA-receptors are glutamic and aspartic amino acids. Therefore, regulation of the level of these excitatory amino acids by means of metabolic therapy has a certain impact on training and retention. However, such states as adventitious movements and hyperactivity of children are related to overactivation of these receptors. Therefore, application of their blockers (Cerebron, Cerebron-P, etc.) helps to cope fast with these problems. We have managed to show that it is hyperactivation (hypersensitivity) of AMPA-receptors that is more significant in initiation of such pathological conditions (hyperactivity, hysterics, obstinacy, adventitious movements).
It is impossible to consider the influence of neurotransmitters-activators without the impact of inhibitory as well as modulator neurotransmitters (these are also amino acids or their derivatives). These problems can be also solved with the help of metabolic therapy. If a child is a poor learner or his/her behavior at school leaves much to be desired, its not his/her fault. The reason is the specific features of the neurochemical processes. One can safely say that neurotransmitter and electrophysiological processes of a child with an excellent (good) progress and adequate behavior are well-balanced, which is reflected in an ideal EEG.
Typical school problems are poor comprehension and retention of the material, rapid fatigability, restlessness, problems with peers. The EEG demonstrates dysrhythmia, lack of zonal differences and hypersynchronous paroxysmal activity at overbreathing. When metabolic therapy selected with the help of EEG monitoring is prescribed, the clinical symptoms and signs and, accordingly, the EEG picture gradually normalize.
Many scientists think that the attention deficit and hyperactivity disorder has the same root causes: pre-delivery, intrapartum and postpartum. After birth the majority of such children had the diagnosis of perinatal encephalopathy or minimal cerebral dysfunction. Then everything was compensated. However, school loads brought back the forgotten problems as during the entire period the nervous system maturation had been developing with a delay. Hence bad memory, behavior, school performance. Therefore, the EEG shows an insufficiently organized rhythm, signs of brainstem dysfunction. This means that the brains needs metabolic assistance and, possibly, rather long-term one. It must be aimed at ensuring maturation and development of the nervous system. The more so if puberty is ahead.




Stress is not just bad mood, fatigability, irritability, somnipathy, weak memory. This is the top of the iceberg, that is something that we see and feel. But its basis is the oxidative stress at the cellular level.  We get an interesting situation. Oxygen is necessary for life. At the same time it is the strongest poison oxidating any substrates, including those necessary for life activities. Oxygen turns them into harmful substances that, in their turn, launch whole chains of catalytic biochemical shifts that result in destruction of membranes and genetic material of human cells. To prevent that the human body has a multilevel antioxidant protection (including numerous components: glutathione, catalase, ascorbic acid, tocopherol, ceruleoplasmin, etc.).
And it is only a well-balanced and well-functioning system of antioxidant protection that allows to safeguard the body from the destructive action of oxygen.
Therefore, any Red-ox dyscrasia, that is oxidation-antioxidant imbalance, has the most destructive consequences at the level of body cells and tissues, which may trigger off practically any disease, including an oncological one.
Metabolic therapy of the Medical center Primavera medica includes a group of preparations restoring the antioxidant protection of the body both at the cellular and tissular as well as organismic level. Oxidative stress does not develop in a separate organ, the process involves the entire body and, first and foremost, affects the nervous system (insomnia, irritability, etc.). There seems to occur an imbalance between the excitatory and inhibitory processes in the brain. Therefore, it is obvious that one cannot do without correction of these neurotransmitter processes. The useful role of antioxidants is well-known. Pharmacies have a lot of drugs containing antioxidants. In this connection I would like to draw your attention to 2 points:
1. Many antioxidants available in pharmacies and included in complex medicines are not absorbed in the intestine or are oxidated immediately after getting into the blood from the intestine thus producing a pro-oxidant (i.e. harmful) rather than oxidant effect.
2. Some antioxidant also become pro-oxidants after penetrating into the cell in excess amounts, thus further aggravating the situation (ascorbic acid, for example).
Therefore, treatment of oxidative stress is a responsible task and it should be provided together with medical specialists.


The proposed hormone treatment as well as treatment with β-interferon and copaxone has its pros and contras. Hormone treatment certainly decreases exacerbation. However, the side effects are quite pronounced. Besides, further application of hormones demands higher doses. β- interferon and copaxone are proposed to reduce the frequency of exacerbations. Clinical studies of large groups of patients do show the statistically average effectiveness of this indicator. However, how can one judge about the effectiveness of these drugs for a particular patient with an ongoing intermittent course of the disease?
What can metabolic therapy of Primavera offer for sclerosis multiplex treatment? Over 12 years about 1200 patients with this disease have received metabolic therapy, more than 80% of them have received over 2-3 courses. Analysis of the effectiveness allows a well-founded conclusion: in the absolute majority of cases (more than 65%) metabolic therapy can maintain the patients state at the initial level during 7-12 years. Besides, during the first-second courses of the treatment more than half of the patients succeed in regaining some part of the lost functions and decreasing the neurological deficit (pelvic functions disorder, strength and muscle tone, coordination) but it takes 2-3 courses annually to achieve such results.



We are referring to the medication that we have been using for about 6 years. It has an equally good effect on benign tumors given in the name of the section. This medication is Sevit-forte. The treatment rate is over 95%. The treatment duration is from 30 to 100 days. Over this period the tumor decreases by 25 - 65 %.
It is possible to predict the result (the tumor decrease rate) even before the start of the treatment. The secret is quite simple: everything depends on the quantity of the fibrous connective tissue in the tumor. The older the tumor (hence, its size), the more marked is its fibrosis and hyalinosis. During treatment the tumor tissue regresses while the fibrous tissue remains. But being a ballast this tissue is not dangerous.
Long-term and meticulous experiments allowed to identify the unique processes of emergence of a tumor cell as well as its death under the impact of Sevit-forte.
We managed to discover that a certain metabolic product that is destroyed in a sound cell preserves and accumulates fast in tumor cells. It blocks expression of the genes with coded protein-receptors regulating the level of ++ ions in a cell (the so-called IP-3 receptors). As a result the cell is short of ++, and the worst affected is the main metabolic cascade pathway providing any function of any cell. The cell cannot perform its function and starts proliferating, that is become a tumor cell. We managed to show that Sevit-forte (both in the cells of benign and malignant tumors):
1. Fragments this very harmful metabolic product;
2. Boosts the ++ level in tumor cells (without affecting the level of internal ++ in sound cells).
3. Brings about fast death of tumor cells (both benign and malignant) through apoptosis but, mostly, through aponecrosis.
In conclusion, I would like to emphasize that Sevit-forte has no adverse reactions and no complications. Firstly, it follows from the mechanism of its action (it affects only the pathological substrate existing in tumor cells only).
Secondly, Sevit-forte is, in fact, a derivative of a natural substance: squalen. And squalen is a necessary participant of metabolism of every human.
Thirdly, we have shown in the experiment that normal cells both highly differentiated and growing do not respond to the presence of Sevit-forte.
In conclusion it should be emphasized that treatment of hysteromyoma and prostatic hypertrophy by means of Sevit-forte is the only nonhormonal and surgery-substitute method of treatment.


From our birth and throughout our life the electrical activity rhythm rate of the brain grows (from 1-2 pulses with babies up to 15 and more with elderly people). Other characteristics of brain activity change as well: amplitude, modulation, response to various factors (photostimulation, deep breathing, etc.). An optimal EEG forms starting from 7-8 years and up to the age of 40-50 (the so-called a-rhythm with the rate of 7-13 Hz and the amplitude of 70-100 uV). With age the rhythm increases and the amplitude decreases. Memory decline, the person becomes less energetic4generally speaking, ageing starts. It is obvious that brain activity declines and, hence, there is a decline of activity of the cortex, pituitary-hypothalamic area and other important brain zones (though there are no unimportant brain zones). An interesting fact about the pituitary-hypothalamic brain area is that it is the supreme regulator of the entire hormonal activity of the body. Its lower activity results in reduced hormone generation with all that it implies (including issues of human ageing). Reduced cortex activity means lower intellectual possibilities.
It is clear that these processes are also based on changes of metabolic neurochemical mechanisms, i.e. a different correlation between the activating, inhibitory and modulating pools of neurotransmitters as well as the functional activity (and quantity) of receptors perceiving them. It seems evident at first sight that to improve memory, to intensify activity of an elderly person it is necessary to increase the fund of activators-neurotransmitters. But it turns out to be quite the contrary.
The numerous studies with volunteers of various age (the volunteers being the employees of Medical center Primavera medica) have shown that the use of light blockers of AMPA and NMDA-receptors (the activators) together with drugs increasing the fund of inhibitory neurotransmitters allowed to slow down this hurried brain rhythm (from 15-18 to 10-11). The rhythm became high-amplitude and modulated. Generally speaking, the situation was like in ones better years. The cognitive functions change fast for the better: memory, comprehension of information. The mood also becomes better and steadier.
This concept is rather young. It is still necessary to check whether the hormonal background changes and to conduct some clinical studies on life expectancy but this will take about 150-200 years.
We do not profess to have discovered apples of eternal youth. And we do not claim that we can slow down ageing (but we hope to be able to do it). But this example convincingly demonstrates the impact of metabolic therapy on neuronal brain process and human body as a whole.
One more essential observation: metabolic medications are not effective in case of a normal EEG: they cannot change brain activity and, accordingly, the EEG picture. This is understandable: a sound brain with a steady functional ability adequately responds to any impact and compensates it.


One can safely assert that this therapy has no side effects and complications. However, one needs skills to apply it. This especially holds true for the group of drugs activating the work of neurons. A relative contraindication to their use is epilepsy. This problems may be avoided by means of electroencephalography that must be mandatorily made before the start of the treatment as well as by means of EEG monitoring and follow-up control.

of Medical center PRIMAVERA MEDICA

METABOLIC PREPARATIONS are referred to the BAA group (biologically active additives). They have been developed and studies in accordance with the RF legislation and entered into the Federal Register of BAA of the Ministry of Healthcare of the RF. Medical center PRIMAVERA MEDICA produces 27 names of authors METABOLIC PREPARATIONS. Each of them has its own value and is used to eliminate a certain symptom of the disease. However, the clinical practice more often faces with a whole aggregate of symptoms; therefore, one has to use treatment regimens including several healing preparations.

The researches involving development of METABOLIC PREPARATIONS and study of treatment methods are conducted by Medical center PRIMAVERA MEDICA together with the leading specialized institutes. They include the Russian State Medical University (chair of neonatology, chair of pediatrics with infantile infections), the Institute of Higher Nervous Activity of the RAS, the Russian Medical Academy of Postgraduate Education (department of infantile toxicology, chair of clinical toxicology), the Research Institute of Pediatrics of the RAMS (department of neonatology), the 6th Childrens Mental Hospital of Moscow of the DH of the RF, the Childrens Municipal Hospital N21 of the DH of Moscow, the Childrens Municipal Clinical Hospital N13 named after N.F. Filatov of the DH of Moscow, the Research Institute of Eye Diseases of the RAMS, the Moscow State Medical-Dental University (chair of infectious diseases, chair of psychiatry, addictions and psychotherapy), the Research Institute of Emergency named after N.V. Sklifosovsky (department of toxicology), the Research Institute of Experimental Diagnosis and Therapy of Tumors of the Oncological Scientific Center named after N.N. Blokhin of the RAMS, the Research Institute of Procurement of New Antibiotics of the RAMS, the Research Institute of Infantile Hematology of the MH of the RF, the Research Institute of Virology named after D.I. Ivanovsky of the RAMS, the HSC Institute of Biophysics of the Federal Department for Bio-Medical and Extreme Problems under the MH of the RF, the Orenburg State Medical Academy (specialized chairs), the Clinic of Neonatology of the MH of the Republic of Bulgaria and others.
In accordance with the General Agreement on joint activities between the Medical center PRIMAVERA MEDICA and the Department of Healthcare of Moscow the effectiveness of METABOLIC THERAPY was studied for newborns with different degrees of immaturity having evident signs of perinatal damage of the central nervous system. It was proved that the use of METABOLIC THERAPY ensures fast normalization of newborns reflexes and other neurological symptoms, including securing of the sucking reflex, which is especially vital for small premature and immature infants. Besides, there occurs fast involution of the syndrom of intracranial hypertension and heightened nervous-reflectory irritability. The catamnesis observation showed that the children who had received METABOLIC THERAPY developed better during their first year. The result of this work was the newsletter of the Department of Healthcare of Moscow Experience of Use of METABOLIC THERAPY in Integrated Treatment of Perinatal Damage of the Central Nervous System intended for head physicians of childrens hospitals, specialists in neonatology and pediatricians.
In 2001 the Executive Committee of the Union of Pediatricians of Russia recommended the guidance manual METABOLIC THERAPY IN PEDIATRICS for use as a manual for pediatricians.
In 2003 the Department of Healthcare of Moscow approved Guidelines for Application of METABOLIC THERAPY Preparations for Treatment of Perinatal Damage of the Central Nervous System and Infantile Cerebral Paralysis.
In 2004 the Department of Healthcare of Moscow published the Newsletter for head physicians of hospitals on application of BAA Aminovit in treatment of alcohol addicts.
In 2004 the clinical trials in basic clinics of the Department of Healthcare of Moscow were completed and reports were prepared on clinical effectiveness of METABOLIC THERAPY preparations in treatment of pscho-speech delays, autism, stammering and addiction.

Structure of the METABOLIC THERAPY network

METABOLIC THERAPY has become widely spread. To ensure wider availability for patients of METABOLIC THERAPY the Medical center PRIMAVERA MEDICA has partnership relations with medical facilities of Russia, neighbouring and far-abroad countries (information on addresses and phone numbers can be obtained at the Medical center PRIMAVERA MEDICA).

Alter Ego Rehabilitation Centre

Human Rights & Friendship Streets

P.O. Box 53642, Limassol, Cyprus. (00357) -334567, -334660
Rehabilitation Centre -
New Medical Technologies

Na Vaclavce 44, Smichov, 150 00, Praha 5, Prague

Czech Republic. (004202 5) -1562322, -1563320


37, Philip Makedonski Street

Plovdiv 4002, Bulgaria. (0035932) 650872, - 650871

Clinic "REVIDA"

Bistricka br, 22 ,Belgrad,
Yugoslavija. (00381 11) -32-93-441, -32-93-442

Medical Center Biodar

Manuilskogo St. 1, Khartsyzsk, Donetsk region, Ukraine (10-38-06257) 4-32-28, fax 4-64-45

Childrens Clinical Hospital

Oktyabrskaya St. 108, Blagoveshchensk, 675000. (- 416-2) phone 444-873

Manus LLC

1st Morskaya St. 4, Vladivostok, 690091.
(- 4232) 41-41-41, mobile 90-64-64 fax 41-14-65

Medical center Nevron LLC

Ostryakova Pr. 27, Vladivostok, 690091.
(- 4232) 25-14-62 (reception), fax 26-74-26

Neiromed LLC

Zemlyachki St. 74, Volgograd. 400138.
(- 8442) 39-86-92, fax 34-73-89

Regional Childrens Clinical Hospital

Lomonosova St. 114, Voronezh, 394000.
(- 0732) phone/fax 53-92-43, mobile40-40-88

Non-Medicinal Medicine LLP 

Gorkogo St. 20, Krasnoyarsk, 660022.
(- 3912) 27-67-00, fax 21-83-11

Medical Health Center CJSC

Zhukova St. 5, Nizhnevartovsk, 626440.
(-3466) 12-09-82, 23-57-66, fax 12-11-22

Salyus LLC

Kropotkina St. 98/2, metro station Gagarinskaya Novosibirsk. (383) 226-55-86, 348-31-40 fax

Regional Childrens Clinical Hospital

Kuibysheva St. 27, Omsk. 644001.
(- 3812) 36-16-40, phone/fax 36-22-20

Municipal Central Childrens Clinical Hospital

Kobozeva St. 25 A, Orenburg. 460000.
(- 3532) 72-00-00, fax 72-90-36

Regional Childrens Psychoneurological Hospital

Konstitutsii St. 11/1, Orenburg, 460044.
(- 3532) fax 36-23-96, 36-13-91

DATC Zdorovie

Ostrovskogo Per. 42, Rostov-on-Don, 344082.
(- 863) phone 240-69-70, fax 243-46-52

Non-Governmental Association Vozrozhdenie

Kuibysssheva St. 113, Samara, 443099.
(- 846) 333-21-14, 333-24-56

Vita LLC

Kamennoostrovsky Pr. 40, Saint Petersburg. 197022.
(- 812) 346-40-15

Pharmacy N406

Mechta A LLC

Lenina St. 406, Stavropol, 355029
(- 8652) phone/fax 35-17-21

Center of Manual Medicine LLC

Amyrsky boulevard 17, Khabarovsk, 680000.
(- 421-2) phone/fax 309-309

Indications for


  • perinatal damage of the central nervous system

and its consequences

  • minimal cerebral dysfunction

  • infantile cerebral paralysis

  • consequences of neuroinfection

(meningoencephalitis, postvaccinal, etc.)

  • consequences of craniocerebral injuries

  • oligophrenia

  • psycho-speech delay

  • autism

  • school problems

  • Attention deficit and hyperactivity disorder

  • epilepsy


Chromosome diseases:

  • Klinefelter syndrome

  • Turner syndrome

  • Down syndrome

  • 8-trisomy syndrome

  • 9-trisomy syndrome

  • cats cry syndrome

  • and other syndromes caused by numerical or

structural changes of chromosomes

Singe-gene syndromes:

  • Noonans syndrome

  • Coffin-Lowry syndrome

  • Coffin-Siris syndrome

  • Cohen syndrome

  • Dubowitz syndrome

  • Marden-Walker syndrome

  • Seckel syndrome

  • other hereditary and nonheritable syndromes accompanied by psychomotor, speech and physical retardation 

  • De Lange syndrome

  • Sotos syndrome

  • Rett syndrome

  • Prader-Willi syndrome

  • Wiiliams syndrome and other syndromes

Single-gene hereditary diseases of the central nervous system:
  • Wilsons disease

  • Huntingtons chorea

  • Hallervorden-Spatz disease

  • hereditary spinocerebellar

degenerations (hereditary ataxia)

  • Friedreich disease

  • spastic ataxia

  • Dejerine-Thomas atrophy

  • Louis-Bar syndrome and other syndromes

  • hereditary spastic paraplegia

Hereditary metabolic diseases:
  • phenylketonuria

  • tuberous sclerosis

hereditary diseases of the neuromuscular system:
  • congenital structural myopathies and dystrophies

  • muscular dystrophy progressive (Duchenne, Becker, Emery-Dreifuss, fascioscapulohumeral muscular dystrophy, etc.)

  • spinal muscular atrophies (Werdnig-Hoffman amyotrophia, Kugelberg-Welander disease, etc.)

  • hereditary monosensory neuropathy

(Roussy-Levi ataxia-areflexia,

Charcot-marie atrophy, etc.)

Mitochondrial diseases.


  • consequences of a stroke

  • consequences of a traumatic brain injuries

  • multiple sclerosis (and other degenerative neuropathies)

  • epilepsy

  • Parkinson disease

  • ALS syndrome

  • neuralgia

  • neuritis

  • radicular pain (osteochondrosis)

  • migraine

  • polyneuropathy

  • vertebrobasilar insufficiency

  • vegetative-vascular dystonia

  • neurosis

  • benign tumors of the nervous system


  • hysteromyoma

  • endometriosis


  • optic atrophy

  • age-related retinal dystrophy

  • oculomotor disorders

  • nystagmus

  • paralytic esotropia

  • oculogyric paresis

  • corneal dystrophy

  • cataract

  • filamentary keratitis

  • keratoconus

  • retinitis pigmentosa

  • corneal opacity

  • posttraumatic eye damage

  • progressive myopia

  • transplant disease (after keratoplasty)

  • Sjogren disease (filamentary keratitis)

  • erosion of cornea, etc.


  • prostatic hypertrophy

  • anal fissure

  • hemorrhoids

  • nonspecific ulcerative colitis

  • obliterating endarteritis or atherosclerosis of lower limbs

- decubitus

  • trophic ulcer of lower limbs

  • peptic ulcer

  • contractures, including posttraumatic and Dupuytrens contractures)




METABOLIC THERAPY supposes outpatient care. This means that patients periodically (every 5-7 days) visit the physician for examination and treatment adjustment as the state of the patient changes rather fast under the influence of METABOLIC THERAPY.
The course of treatment for different diseases varies from 10-12 days (hemorrhoid treatment, for example) or 56-60 days (treatment of infantile cerebral paralysis, psycho-speech delay) to 85-115 days (treatment of hysteromyoma).
With some diseases one course of treatment is sufficient. Such diseases, as infantile cerebral paralysis or psycho-speech delay, depending on the form and severity, require 3-4 and in severe cases even 5-7 courses of treatment. In such cases the treatment-free intervals are 1-1.5 months. Degenerative diseases of the nervous system need 2-3 courses annually.
Patients are received by highly qualified physicians: geneticists, gynecologists, neurologists, oncologists, oculists, psychoneurologists, surgeons, etc. during treatment all the necessary examinations are carried out for diagnosis and objective treatment control. Medical center PRIMAVERA MEDICA is equipped with modern ultrasonic, ophthalmologic and gynecologic equipment; it carries out psychophysiological examinations, electroencephalography and brain echoencephalography; practically any laboratory clinical, biochemical and immunologic blood analyses.
The well-equipped convalescence home using all the necessary modern methods ensures mastering the patients new motor abilities received during METABOLIC THERAPY.

When we were preparing the booklet, we planned it, as usual, as an information-promotional one but it rather turned out to be a scientific-informative booklet. We decided not to load it with percents, figures of the therapy effectiveness statistics or the growing number of the patients coming to us. This information can be seen on the web-site displaying the results and reports of various clinical researches.
Some diseases were not covered in much detail, such as consequences of a stroke and traumatic brain injury, Parkinson disease, a large group of hereditary diseases (first of all, Downs syndrome), endometriosis (gynecology), hemorrhoid, obliterating disease of lower extremity arteries, colitis (including nonspecific ulcerative colitis), addictions (alcohol, drug addiction, excessive gambling). The reason is simple. This booklet presents our achievements, knowledge, concepts, theories. Some experimental data have the status of discoveries. Use of metabolic therapy and its effectiveness for these diseases has been tried and tested tactically and by time.
Does metabolic therapy always help?

Practically it does. It may be said that if metabolic therapy does not provide the desired result in some case, the reason is most likely to be the unskilled prescription. Thats why only experienced, highly-qualified, thinking physicians and excellent scientists work in Primavera medica.


1993. Medication for cerebral diseases
1993. N 2014082 Method of diagnosis of oncological diseases
2001. N WO 02/092066 A1 Antitumoral agent having no side effects
2001. N 2182480 Antitumoral agent and method of obtaining it
2001. N 2197957 Preparation and method of eliminating the side effect of antitumoral agents.
2002. N 2245143 Amino-acid agent having an antitumoral effect and method of obtaining it
2002. N 2238723 Analgetic and anticontracture body agent
2003. N 2252756 Agent against alcohol and drug addiction, method of obtaining the agent


Biochemical Basics of Metabolic Therapy of Primavera. (European Research Journal "OM & Ernahrung", Zurich-Stuttgart-Salzburg, 2006, N 115) Dotsenko A.N., Cand. M.Sc.
Metabolic Therapy in Treatment of Cerebropathy. (Report at the 50th Annual Congress of the World Organization of the Human Brain. Wyndmoor, Pennsylvania, USA, May 4-6, 2005) Dotsenko A.N., Cand.Sc.(Med.)
Metabolic Therapy in Treatment of Infantile Cerebropathy. (Report at the Symposium on Orthomolecular Medicine. Prague, Czech Republic, February 25-27, 2005) Blinnikova O.E., Cand.Sc.(Med.), associate professor, geneticist; Dotsenko A.N., Cand.Sc.(Med.)
Influence of Amino-Acid Composites on Electrophysiological Parameters and Functional Activity of Neurons, Neurophysiological Analysis. (Report at the Symposium on Orthomolecular Medicine. Prague, Czech Republic, February 25-27, 2005) Kudrayshov I.E., Cand.Sc. (Biol.); Dotsenko A.N., Cand.Sc.(Med.)
Role of Metabolic Therapy in Treatment of Adult Epilepsy. (European Research Journal "OM & Ernahrung", Zurich-Stuttgart-Salzburg, 2005, N 110) Roshchina N.A., Cand.Sc.(Med.), associate professor, neurologist; Dotsenko A.N., Cand.Sc.(Med.)
Therapeutic Effectiveness of Biologically Active Additives in Addiction Treatment (European Research Journal "OM & Ernahrung", Zurich-Stuttgart-Salzburg, 2004, N 109) Dotsenko A.N., Cand.Sc.(Med.); Khokhlov A.P., Doctor of Medicine, Professor; Shamov S.A., Cand.Sc.(Med.), associate professor; Markin E.E..
New Concept of Pathogenesis and Treatment of Amyotrophic Lateral Sclerosis (ALS). (European Research Journal "OM & Ernahrung", Zurich-Stuttgart-Salzburg, 2004, N 108) Khokhlov A.P., Doctor of Medicine, Professor; Dotsenko A.N., Cand.Sc.(Med.); Roshchina N.A., Cand.Sc.(Med.), associate professor, neurologist.
 Metabolic Therapy in the Clinical Picture of Perinatal Nervous System Disturbances and ICP. (European Research Journal "OM & Ernahrung", Zurich-Stuttgart-Salzburg, 2004, N 107) Khokhlov A.P., Doctor of Medicine, Professor; Semenova K.A., Doctor of Medicine, professor, Honoured Science Worker of the RSFSR; Dotsenko A.N., Cand.Sc.(Med.)
Impact of the New Squalen Derivative Sevit-F on Human Tumor in Nude Mice. (Theoretical and Academic and Research Journal Russian Biotherapeutical Journal Moscow, 2004, N 2, v. 3) Khokhlov A.P., Doctor of Medicine, Professor; Treshchalina E.M., Doctor of Medicine.; Dotsenko A.N., Cand.Sc.(Med.); Sedakova L.A.; Andronova N.V., Cand.Sc.(Med.).; Gerasimova G.K., Doctor of Medicine, Prof..
Application of Biologically Active Additive Aminovit in Treatment of Alcohol Addicts. Newsletter of the Department of Healthcare of Moscow, 2004.
Correction of Psychoneurological Development and Phenotype of Patients with Down Syndrome with Underlying Metabolic Therapy. (European Research Journal "OM & Ernahrung", Zurich-Stuttgart-Salzburg, 2003, N 106) Khokhlov A.P., Doctor of Medicine, Professor; Blinnikova O.E., Cand.Sc.(Med.), associate professor, geneticist.
Prospects of Using Amino-Acids in Neurology and Oncology. (European Research Journal "OM & Ernahrung", Zurich-Stuttgart-Salzburg, 2003, N 105) Khokhlov A.P., Doctor of Medicine, Professor; Dotsenko A.N., Cand.Sc.(Med.)
Metabolic Therapy in Clinical Picture of Perinatal Nervous System Disturbances and ICP. (Report at the Research and Practice Conference of Pediatricians of Russia. Moscow, Russia, September 23-24, 2003. Academic and Research Journal of the Union of Pediatricians of Russia Pharmacopeia in Pediatrics Moscow, 2003, v. 2, Annex N2) Khokhlov A.P., Doctor of Medicine, Professor; Semenova K.A., Doctor of Medicine, professor, Honoured Science Worker of the RSFSR; Dotsenko A.N., Cand.Sc.(Med.)
Cytotoxic Effect of Sevit-F Preparation and Aged Amino-Acids on H-( Cell Culture of Human Lymphatic Leukemia. (Theoretical and Academic and Research Journal Russian Biotherapeutical Journal, Moscow, 2003, N 1, v. 2) Khokhlov A.P., Doctor of Medicine, Professor; Dotsenko A.N., Cand.Sc.(Med.); Osipova E.Yu., Doctor of Biology; Astrelina T.A., cand.Sc.(Med.); Belokhvostov A.S., Doctor of Medicine
Results of Screening of the New Squalen Derivative for Antitumoral Activity. (Theoretical and Academic and Research Journal Russian Biotherapeutical Journal, Moscow, 2003, N 1, v. 2) Khokhlov A.P., Doctor of Medicine, Professor; Dotsenko A.N., Cand.Sc.(Med.); Treshchalina E.M., Doctor of Medicine.; Sedakova L.A.; Andronova N.V., Cand.Sc.(Med.).; Gerasimova G.K., Doctor of Medicine, Prof..

Molecular Basics of the Mechanism of Chronic Stress Formation. (European Research Journal "OM & Ernahrung", Zurich-Stuttgart-Salzburg, 2003, N 104) Khokhlov A.P., Doctor of Medicine, Professor; Dotsenko A.N., Cand.Sc.(Med.)
Guidelines for Application of Metabolic Therapy Preparations for Treatment of Perinatal Disturbance of Nervous System and Infantile Cerebral Paralysis. Guidelines of the Department of Healthcare of Moscow, 2003.
Use of Amino-Acid Composites in Infantile Psychotherapeutic Practice. (Selected Materials of the Jubilee Research and Practice Conference Devoted to 10th Anniversary of the Department of Medical Psychology of SamSMU Clinical Psychology and Practical Healthcare, Samara, September 12-13, 2002). Konnov S.V.
Cytotoxic Effect of Sevit-F Preparation on H-9 Cell Culture of Human Lymphatic Leukemia. (Theoretical and Academic and Research Journal Russian Biotherapeutical Journal, Moscow, 2002, N 2, v. 1) Khokhlov A.P., Doctor of Medicine, Professor; Dotsenko A.N., Cand.Sc.(Med.); Belokhvostov A.S., Doctor of Medicine; Osipova E.Yu., Doctor of Biology.; Astrelina T.A., Cand.Sc.(Med.); Vdovichenko K.K., Cand.Sc.(Biol.); Sidorova I.K.
Clinical Picture, Classification, Diagnosis of Ehlerws-Danlos Syndrome with Account for Modern Molecular-Genetic Researches. ("New Surgical Archive", Moscow, 2002, N 4, v. 1) Khokhlov A.P., Doctor of Medicine, Professor; Dotsenko A.N., Cand.Sc.(Med.); Belokhvostov A.S., Doctor of medicine; Osipova E.Yu., Doctor of Biology.; Astrelina T.A., Cand.Sc.(Med.); Vdovichenko K.K., Cand.Sc.(Biol.); Sidorova I.K.
Role of Metabolic Therapy in Treatment of Genetic Diseases. (Report at IV Balkan Congress of Geneticists. Novy Sad, Yugoslavia, August 24-26, 2000. Internal Journal of Medical Genetics "BJMG", Sophia, 2000, N2) Khokhlov A.P., Doctor of Medicine, Professor.
Assessment of Effectiveness of Using Amino-Acid Composite "Provit" in the Complex of Early medical Rehabilitation of Children with Perinatal Disturbances of the CNS. ("Russian Bulletin of Perinatology and Pediatrics", Moscow, 2000, N2) Degtyarev D.N., Doctor of Medicine, Prof., Chief Neonatologist of Moscow; Khachatryan A.V.; Navasardyants D.G., Cand.Sc.(Biol.); Kyshtymov M.V.; Volodin N.N., Doctor of Medicine, Prof., Acad. of the RAMS.
Games and Exercises for Hand Movement Development (Study Guide, Moscow, 1999.) Khokhlov A.P., Doctor of Medicine, Professor; Dotsenko A.N., Cand.Sc.(Med.); Ryabinina I.V.
Approbation of Amino-Acid Composite Provit for Premature Infants with Perinatal Encelopathy. Newsletter of the Research Institute of Pediatrics of the RAMS, 1998.
Change of the Content of Neurospecific Proteins of Neurospecific Enolase, Leucine Aminopeptidase and Cytokine of the Factor of Tumor Necrosis in Children with CNS Disturbances. ("Pediatrics, Moscow, 1998, N5) Volodin N.N., Doctor of Medicine, Prof., Acad. of the RAMS; Degtyarev D.N., Doctor of Medicine, Prof., Chief Neonatologist of Moscow; Khachatryan A.V.; Khokhlov A.P., Doctor of Medicine, Professor; Navasardyants D.G., Cand.Sc.(Biol.)
Metabolic Disorders in Pathogenesis of Perinatal Encephalopathy and Infantile cerebral Paralysis and Possibility of Optimized Treatment of These Diseases. ("Bulletin of Practical Neurology, Moscow, 1998, N4,.) Semenova K.A., Doctor of Medicine, professor, Honoured Science Worker of the RSFSR; Sinitsyn G.P.; Naichuk S.N.; Khokhlov A.P., Doctor of Medicine, Professor.
Effectiveness of Provit Preparation in Treatment of Perinatal CNS Disturbances of Young Children. (Report at the 2nd Congress of the Russian Association of Specialists in Perinatal Medicine, Moscow, September 25-26, 1997.) Dmitrieva N.V., Doctor of Medicine, Prof.; Tkachenko T.G., Cand.Sc.(Med.), associate professor; Dmitriev A.V., Doctor of Ph., prof., Nesterova E.I.; Filimonova I.G.
Motor Gymnastics of Round Remedial Balls for Children and Adults with Cerebral Pathology. (Study Guide, Moscow, 1996.) Khokhlov A.P., Doctor of Medicine, Professor; Tarakanov O.P., Cand.Sc.(Med.), associate professor; Dotsenko A.N., Cand.Sc.(Med.)
New Method of Decreasing the Stress Level with Handicapped Children (Report at II All-Russia Research and Practice Conference Anthropogenic Impacts and Human Health, Kaluga, April 25-27, 1995) Khokhlov A.P., Doctor of Medicine, Professor; Tarakanov O.P., Cand.Sc.(Med.), associate professor; Dotsenko A.N., Cand.Sc.(Med.)
Physiology of Muscular Tone and Voluntary Movements (Study Guide, Moscow, 1994) Andrianov V.V., Doctor of Medicine, Prof.; Tarakanov O.P., Cand.Sc.(Med.), associate professor; Dotsenko A.N., Cand.Sc.(Med.)


clinical trials of metabolic therapy preparations

Clinical trials of metabolic therapy preparations in treatment off psycho-speech delays, autism and stammering. SSC of social and forensic psychiatry named after V.P. Serbsky. Childrens mental hospital N6, Moscow. 2004
Unmasked controlled clinical trial of BAA Aminovit in treatment of alcohol addicts. Moscow State Medical-Dental University, chair of psychiatry, narcology and psychotherapy. Narcological clinical hospital N17 Moscow. 2004 
Unmasked controlled clinical trial of BAA Aminovit and Cerebron-P in couping thebaic withdrawal syndrome. Moscow State Medical-Dental University, chair of psychiatry, narcology and psychotherapy. Narcological clinical hospital N17 Moscow. 2004
Clinical trials of Provit and Sevita in treatment of newborns (mature and immature) with perinatal asphyxia and ischemic damage of the CNS. Ministry of Healthcare of the Republic of Bulgaria, Clinic of neonatology of the university hospital of active treatment of infantile diseases, Sophia, 2003.
Effectiveness of integrated therapy with preparations Sevit-F, Vitamikst-P and Immunol in oncohematological diseases. Research Institute of Infantile hematology of the MH of the RF. Municipal clinical hospital named after S.P. Botkin. 2003
Application of preparation Sevit-K in treatment of severe dystrophic diseases of the photoperceptive eye mechanism. Municipal central childrens clinical hospital. Orenburg, 2000.
Clinical trial of preparations Sevit, Aminovil within the framework of the program Treatment of sick children with exogenous intoxication. Russian Medical Academy of Postgraduate education, chair of infantile toxicology. Childrens municipal clinical hospital N13 of Moscow named after N.F. Filatov, 1999.
Experimental research of effectiveness of preparation Sevit-K in the form of eye drops in treatment of mechanical and thermal cornea injury.  State Institution Research Institute of ocular diseases of the RAMS. 1999.
Clinical trial of preparation Sevit within the framework of the program Treatment of patients with gastritis, gastroduodenitis and gastric and duodenal ulcer. Russian State Medical University, chair of pediatrics with infantile infections. Childrens municipal hospital N21, Moscow, 1999.
Clinical trial of preparations Provit and Sevit for immature children with perinatal damage of the CNS. Scientific center of Children Health of the RAMS, department of immature children. 1998.  
Approbation of amino-acid composite Provit for immature children with perinatal encephalopathy.  Research Institute of Pediatrics of the RAMS, department of neonatology. 1998.
 Clinical trial of biologically active additives for toxicological children. Russian Medical Academy of Postgraduate education, chair of infantile toxicology. Childrens municipal clinical hospital N13 of Moscow named after N.F. Filatov, 1999, Childrens toxicological center, 1998.
Results of follow-up study of children of the basic and control groups during the first year of life. Russian State Medical University, chair of neonatology. Childrens municipal clinical hospital N 13 of Moscow named after N.F. Filatov, 1997.
Clinical trial of additive Vitamikst-P in treatment of viral hepatitis. Moscow Medical Dental University, chair of infectious diseases. Clinical infectious diseases hospital N2 of Moscow. 1997.
Clinical trials of additive Provit for newborns with perinatal damage of the CNS. Russian State Medical University, chair of neonatology. Childrens municipal clinical hospital N 13 of Moscow named after N.F. Filatov, 1996.
Treatment of perinatal encephalopathy of newborns with preparation Provit. Regional clinical diagnosis center for children. Ryazan, 1996..
Results of application of preparation Provit. Childrens out-patient department N100, Moscow, 1996.
Approbation of preparation Provit. Municipal clinical hospital, Vladivostok. 1996.
Treatment of perinatal encephalopathy of newborns with preparation Provit. Municipal childrens diagnosis-rehabilitation center. Orenburg. 1996.


Under the editorship of Khokhlov A.P., Doctor of medicine, Prof.

Medical center PRIMAVERA MEDICA"

Perinatal Encephalopathy. Semenova K.A., Doctor of Medicine, professor, Honoured Science Worker of the RSFSR
Effectiveness of Amino-Acid Composites for Adults with Infantile Cerebral Paralysis. Savin A.A., Doctor of Medicine, Prof..
Metabolic Therapy and Speech Development Disturbances. Ivanushkina I.Yu., psychiatrist.
Dynamics of EEG of Changes in the Process of Metabolic Therapy for Children with Mental Retardation. AndreevaO.V., Cand.Sc.(Med.), physician of functional diagnosis.
Application of Amino-Acid Composites for Treatment of Mental Retardation of ICP patients. Parkanova S.A., psychiatrist. 
Treatment of Patients with Hereditary Syndromal Pathology with Amino-Acid Composites. Blinnikova O.E., Cand.Sc.(Med.), associate professor, geneticist, Demina N.A., Honoured physician of the RSFSR, geneticist.
Prospects of Using Metabolic Therapy for Treatment of Down Syndrome. Khokhlov A.P., Doctor of Medicine, Professor; Blinnikova O.E., Cand.Sc.(Med.), associate professor, geneticist; Demina N.A., Honoured physician of the RSFSR, geneticist.
Application of Amino-Acid Composites for Treatment of Children with Congenital Abnormality of the Central Nervous System  Bezprozvanova T.N., Cand.Sc.(Med.), associate professor, neurosurgeon.
Application of Amino-Acid Composites for Integrated Treatment of Epilepsy. Khokhlov Yu.K., Doctor of medicine, associate professor, neurologist; Fomicheva G.N., physician of functional diagnosis. .
Analysis of Action of Amino-Acid Composites on Neuropsycholoical and Psychopathological Disturbances in Epilepsy and Epileptiform Syndromes. Korableva T.I., psychiatrist. 
Multiple Sclerosis. Khaidarov B.T., Cand.Sc. (Med.), neurologist.
Prospect of Using Amino-Acid Agents for Treatment of Postapoplectic Motor Disorders.  Parfenov V.A., Doctor of medicine, prof., neurologist.
Experience of Prescription of Amino-Acid Composites for Amyotrophic Lateral Sclerosis (ALS) Roshchina N.A., Cand.Sc.(Med.), associate professor, neurologist.
Treatment of Parkinsonism with Amino-Acid Composites.  Gerasimova O.N., Cand.Sc.(Med.), neurologist.
Experience of Applying Metabolic Agents in Narcology Novikov S.P., narcologist
Infantile Cerebral Paralysis and Amaurosis. Possibilities of Eye-Sight Recovery. Yudina Yu.V., Cand.Sc.(Med.), oculist.
Metabolic Therapy in Treatment of Age-Related Cataracts. Yudina Yu.V., Cand.Sc.(Med.), oculist; Yudina E.A., oculist of the highest category; Khokhlov A.P., Doctor of Medicine, Professor.
Metabolic Therapy in Cornea Diseases . Yudina Yu.V., Cand.Sc.(Med.), oculist of the highest category.
Metabolic Therapy of genital Endometriosis.  Ganchina N.I., gynecologist-thyroid specialist.
Experience of Treatment of Hysteromyoma using preparation Sevit-Forte. Agnaeva N.Z., Cand. Sc.(Med.), gynecologist.
Treatment of Benign Prostatic Hyperplasia Using Natural Metabolites. Khokhlov A.P., Doctor of Medicine, Professor; Shirshov O.N., Cand.Sc.(Med.), surgeon; Dotsenko A.N., Cand.Sc.(Med.)
Use of Metabolic Therapy Agents to Eliminate Trophic Ulcers of Lower Limbs. Khokhlov A.P., Doctor of Medicine, Professor; Shirshov O.N., Cand.Sc.(Med.), surgeon; Dotsenko A.N., Cand.Sc.(Med.)
Application of Natural Metabolites in Treatment Anorectal Diseases . Khokhlov A.P., Doctor of Medicine, Professor; Shirshov O.N., Cand.Sc.(Med.), surgeon.
and others.


Videoconsulting is provided in:

Infantile and adult neurology

Infantile psychiatry



To receive a consultation one needs:

Connection to high-speed (both ways) Internet

Registration and support of SKYPE connections (

Web-camera with VGA resolution and even more fine resolution.

Appointment by phone:

(499) 236-50-64

(499) 236-71-22

(499) 237-94-49



31/12 Bolshaya Serpukhovskaya st.

P/ Andreeva st

1st Tchipkovskiy lane

2nd Tchipkovskiy lane

Serpukhovskaya underground station.